Tang, Ming
Abbas, Hussein A. http://orcid.org/0000-0003-2946-3562
Negrao, Marcelo V. http://orcid.org/0000-0001-8938-6699
Ramineni, Maheshwari
Hu, Xin
Hubert, Shawna Marie http://orcid.org/0000-0002-7907-9609
Fujimoto, Junya
Reuben, Alexandre http://orcid.org/0000-0003-4510-0382
Varghese, Susan
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Li, Jun
Chow, Chi-Wan
Mao, Xizeng
Song, Xingzhi
Lee, Won-Chul
Wu, Jia http://orcid.org/0000-0001-8392-8338
Little, Latasha
Gumbs, Curtis
Behrens, Carmen
Moran, Cesar http://orcid.org/0000-0003-1158-5713
Weissferdt, Annikka
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Sepesi, Boris
Swisher, Stephen http://orcid.org/0000-0002-3080-1920
Cheng, Chao http://orcid.org/0000-0002-5002-3417
Kurie, Jonathan http://orcid.org/0000-0002-1472-8719
Gibbons, Don http://orcid.org/0000-0003-2362-3094
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Wistuba, Ignacio I.
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Kalhor, Neda http://orcid.org/0000-0001-6891-6435
Zhang, Jianjun http://orcid.org/0000-0001-7872-3477
Article History
Received: 14 January 2021
Accepted: 16 November 2021
First Online: 6 December 2021
Change Date: 8 April 2022
Change Type: Update
Change Details: In the PDF version of this article, the equal contribution of Ming Tang and Hussein A. Abbas affiliation was incorrectly denoted as 14. The correction number is 11. The PDF has now been corrected.
Competing interests
: Jianjun Zhang reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. J. V. H. reports research funding from AstraZeneca, GlaxoSmithKline, and Spectrum; consultant fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, and Takeda; licensing fees from Spectrum. B. S. reports consultant fees from BMS. M. V. N. reports research funding from Mirati, Novartis, Checkmate, Ziopharm, AstraZeneca, Pfizer, and Genentech; consultant fees from Mirati, Merck/MSD. The other authors declare neither financial nor non-financial interests in the submitted work.